Prescient Therapeutics (ASX:PTX) resolved the technical difficulties facing its OmniCAR program by creating a new generation of improved variants, according to a Thursday Australian bourse filing.
OmniCAR is a CAR(chimeric antigen receptor)-cell platform, that enables controllable T-cell activity and multi-antigen targeting with a single-cell product.
It observed that OmniCAR T-cells unarmed with antigen binders were demonstrating unexpected activity, which ran counter to "the modular, controllable thesis" of the program.
It developed several OmniCAR variants over 2024 in collaboration with the Peter McCallum Cancer Center and Australia's Commonwealth Scientific and Industrial Research Organization, that overcame the issues observed with the previous OmniCAR version in preliminary in vitro and in vivo testing.
When armed with binders, these new variants demonstrated highly effective tumor-killing activity in mice with Her2-positive tumors. The duration of efficacy was more than that of the previous version of the platform.
It will further evaluate these variants in 2025.
The firm's shares rallied 13% in trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。